Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy

CLOSEOUT LETTER Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy MARCS-CMS 570563 — February 06, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Vladimir Lenchitsky Recipient Title Founder and Chairman of the Board Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy 4045 E. Bell Rd. Suite 163 Phoenix , AZ 85032 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States 949-608-2900 Dear Mr. Lenchitsky : The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 570563) dated January 10, 2019. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Steven E Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV Content current as of: 02/10/2020 Regulated Product(s) Drugs